Bioinformatics Unit supports advances in oncolytic virotherapy

A recent publication in Nature Communications from Dr. Eleni Panagioti, the Charles Cook Lab, and colleagues, examined the therapeutic potential of an engineered herpes simplex virus in IDH1-mutant diffuse gliomas. The study found that IDH1-R132H mutant cells exhibit heightened susceptibility to viral infection, and that combining oncolytic HSV-1 with TIGIT checkpoint blockade further enhanced tumor cell killing by promoting an apoptotic environment selectively in IDH1-R132H mutant cells.

The Bioinformatics Unit supported this work by mining and analyzing TCGA bulk RNA-seq data from IDH1-R132H samples to identify viral biomarkers and characterize relevant biological pathways.

• Read the full study here.
• Learn more about the Core and Bioinformatics Unit.